39 reports

  • TYPE 1 DIABETES DRUGS MARKET IN AMERICAS 2015-2020 ($ BILLIONS)
  • TYPE 1 DIABETES DRUGS MARKET IN APAC 2015-2020 ($ BILLIONS)
  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Key Features of the Report: - Type ## Diabetes Patient Flow - Type ## Diabetes Prevalence - Type ## Diabetes Diagnosed Patients - Type ## Diabetes Treated Patients

  • Chronic Disease
  • Type 1 Diabetes
  • Europe
  • World
  • Forecast

Type ## Diabetes Market Forecast ($), Japan, 2015 – 2020 The latest research from Fore Pharma, Global Type ## Diabetes Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Type ## Diabetes pipeline products, Type ## Diabetes epidemi

  • Chronic Disease
  • Type 1 Diabetes
  • France
  • Germany
  • Market Size
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 11.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

Key Features of the Report: - Type ## Diabetes Patient Flow - Type ## Diabetes Prevalence - Type ## Diabetes Diagnosed Patients - Type ## Diabetes Treated Patients

  • Type 1 Diabetes
  • Europe
  • France
  • Germany
  • Forecast
  • Prevalence of Type 1 Diabetes Mellitus, females (000s)
  • TOP-LINE PREVALENCE FOR TYPE 1 DIABETES MELLITUS
  • Chronic Disease
  • Diabetes
  • Pathology
  • Type 1 Diabetes
  • Europe

Global Type ## Diabetes (T##D) Market Trends, By Region ##. ##.

  • Insulin
  • Therapy
  • Type 1 Diabetes
  • World
  • Forecast
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

Type ## Diabetes Market Forecast ($), UK, 2015 – 2020 The latest research from Fore Pharma, Europe Type ## Diabetes Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Type ## Diabetes pipeline products, Type ## Diabetes epidemiolo

  • Type 1 Diabetes
  • Europe
  • France
  • Germany
  • Market Size

Japan Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Japan Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Japan
  • Demand

France Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) France Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • France
  • Demand

Germany Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Germany Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Germany
  • Demand

UK Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) UK Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • United Kingdom
  • Demand

Italy Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Italy Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Italy
  • Demand

US Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) US Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Demand

Spain Type ## Diabetes Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Type ## Diabetes Treatments ##) Type ## Diabetes Pipeline ##) Spain Type ## Diabetes Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Spain
  • Demand
  • 5.4.1 Diagnosed Type 1 Diabetes Patients
  • SALES FOR TYPE 1 DIABETES IN CANADA BY DRUG CLASS, 2013-2023
  • Type 1 Diabetes
  • Canada
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Drug analysis: Farxiga

9091 10000 7727

It is approved for the treatment of type ## diabetes and currently in Phase III trials for the treatment of type ## diabetes.

  • Diabetes
  • Type 1 Diabetes
  • Europe
  • Japan
  • United States
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • VACCINE FOR TYPE 1 DIABETES - DRUG PROFILE
  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative
  • Type 1 Diabetes (Juvenile Diabetes) - Overview
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • Cell Therapy
  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative

Type ## Diabetes Pipeline by Stages ##.

  • Chronic Disease
  • Type 1 Diabetes
  • Product Initiative
  • Type 1 diabetes (Juvenile Diabetes)
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • Biotechnology
  • Type 1 Diabetes
  • Company
  • Product Initiative
  • AstraZeneca PLC
  • Aug 31, 2017: Role of gut bacteria in averting Type 1 diabetes
  • Jul 12, 2016: Defymed Receives Support from JDRF to Fight Type 1 Diabetes
  • Diabetes
  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • GlobalData's company
  • 7.1.2.2 MARKET SEGMENTATION - BY LOCALIZED AUTOIMMUNE DISEASE- TYPE 1 DIABETES
  • More than 20% of the UAE population suffers from arthritis of one kind or the another.
  • Autoimmune Disease
  • Diagnostics
  • Type 1 Diabetes
  • World
  • Market Size
  • 07/21/2016: VIACYTE AWARDED NEW CIRM GRANT TO DEVELOP PEC-DIRECT FOR HIGH-RISK TYPE 1 DIABETES
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES
  • Therapy
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • ViaCyte, Inc.
  • 01/05/2017: ADOCIA LAUNCHES NEW MULTI-HORMONAL COMBINATION PROJECT FOR TREATMENT OF TYPE 1 DIABETES
  • Healthcare
  • Insulin
  • Pharmaceutical
  • Type 1 Diabetes
  • Adocia
  • BIOARTIFICIAL PANCREAS - TYPE 1 DIABETES - PRODUCT STATUS
  • BIOARTIFICIAL PANCREAS - TYPE 1 DIABETES - PRODUCT DESCRIPTION
  • Clinical Trial
  • Endocrine Disease
  • Type 1 Diabetes
  • United States
  • GlobalData's company